CRISPR Therapeutics AG — Director's Dealing 2018

Jul 6, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-07-03

Reporting Person: CAGNONI PABLO J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-03	Common Shares	M	5816	$5.59	Acquired	5816	Direct
2018-07-03	Common Shares	S	5816	$62.00	Disposed	0	Direct
2018-07-05	Common Shares	M	1684	$5.59	Acquired	1684	Direct
2018-07-05	Common Shares	S	1684	$62.00	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-03	Stock Option (Right to Buy)	$5.59	M	5816	Acquired	2025-11-04	Common Shares (5816)	Direct
2018-07-05	Stock Option (Right to Buy)	$5.59	M	1684	Acquired	2025-11-04	Common Shares (1684)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This option was granted on November 4, 2015 with respect to 93,833 Common Shares with 100% of the shares vesting in 48 equal monthly installments thereafter.